Design of biorelevant test setups for the prediction of diclofenac in vivo features after oral administration

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1483-1501

  Guhmann, Marie ^a,b   Thommes, Markus ^c   Gerber, Frédéric ^b,d   Pöllinger, Norbert ^b   Klein, Sandra ^a   Breitkreutz, Jörg ^c   Weitschies, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b GLATT GMBH   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

biorelevant test setups; diclofenac; mouth exposure; multiple absorption peaks; orodispersible tablets

Indexed keywords

DICLOFENAC; DICLOFENAC POTASSIUM;

ARTICLE; DELAYED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTESTINE FLUID; MEAN RESIDENCE TIME; NONBIOLOGICAL MODEL; PARTICLE SIZE; PH MEASUREMENT; PRECIPITATION; PREDICTION; PRIORITY JOURNAL; SALIVA; SIMULATION; STOMACH EMPTYING; STOMACH JUICE; SUSTAINED DRUG RELEASE; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DICLOFENAC; GASTRIC EMPTYING; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PARTICLE SIZE; PHARMACEUTICAL SOLUTIONS; SALIVA; SOLUBILITY; STOMACH; SUSPENSIONS;

EID: 84877732745     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0974-y     Document Type: Article

References (43)

1. Song NN, Zhang SY, Liu CX. Overview of factors affecting oral drug absorption. Asian J Drug Metab Pharmacokinet. 2004;4(3):167-76.
2. Davies NM, Takemoto JK, Brocks DR, Yanez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet. 2010;49(6):351-77.
3. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HR, et al. Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci. 2009;98(4):1206-19.
4. Sallmann AR. The history of diclofenac. Am J Med. 1986;80(4B):29-33.
5. Macia MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther. 1995;33(6):333-9.
6. Lötsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, et al. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. Pharm Res. 2000;17(1):77-84.
7. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther. 2000;38(11):546-51.
8. Bettini R, Giordano F, Donini C, Massimo G, Catellani PL, Colombo P. Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets. STP Pharm Sci. 2000;10(4):335-9.
9. Tabata K, Yamaoka K, Fukuyama T, Nakagawa T. Local absorption kinetics into the portal system using the portal-venous concentration difference after an oral dose of diclofenac in the awakening rat. Accelerative effect of bile on intestinal absorption of diclofenac. Drug Metab Dispos. 1996;24(2):216-20.
10. Mahmood I. Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. J Pharm Pharmacol. 1996;48(12):1260-3.
11. Garbacz G, Wedemeyer RS, Nagel S, Giessmann T, Mönnikes H, Wilson CG, et al. Irregular absorption profiles observed from diclofenac extended-release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. Eur J Pharm Biopharm. 2008;70(2):421-8.
12. Wilding IR, Hardy JG, Sparrow RA, Davis SS, Daly PB, English JR. In vivo evaluation of enteric-coated naproxen tablets using gamma scintigraphy. Pharm Res. 1992;9(11):1436-41.
13. Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung. 2001;51(11):885-90.
14. Chan KKH, Mojaverian P, Ziehmer BA, John VA. Application of radiotelemetric technique in evaluating diclofenac sodium application after oral administration of various dosage forms in healthy volunteers. Pharm Res. 1990;7(10):1026-32.
15. Novartis Pharma. Voltaren Dispers. Fachinformation MS 12/8.8. Nov. 2008.
16. Murphy LM, Matthews GP. US Patent 5,256,699 dispersible tablet formulation of diclofenac acid free base. US Patent Office. 1993 October 26.
17. Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. Open Drug Deliv J. 2010;4(2):2-13.
18. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption immediate release dosage forms. Pharm Res. 1998;15(1):11-22.
19. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12(3):397-406.
20. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci. 2009;37(3-4):434-41.
21. HamLen S, MacGregor K. Patient compliance study: new data shows drug delivery has positive impact on patient compliance. Drug Dev Deliv. 2011;11(7):30-3.
22. Malvern. Determination of the particle absorption for laser diffraction size calculations [Internet]. 2009 [cited 2010 June 02]. Available from: http://www.malvern.com/malvern/kbase.nsf/allbyno/KB002041/$file/ MRK1308-01.pdf.
23. Kippax P. Appraisal of the laser diffraction particle-sizing technique. Pharm Technol. 2005;9(3):88-96.
24. Preis M, Pein M, Breitkreutz J. Development of a taste masked orodispersible film containing dimenhydrate. In: Proceedings of the 2nd Electron. Conf. Pharm. Sci. Sciforum Electronic Conferences Series. 2012 May 1-31.
25. Hugues L, Gehris A. A new method of characterizing the buccal dissolution of drugs. Spring House: Rohm and Haas Research Laboratories; 2003.
26. Tan YTF, Peh KK, Al-Hanbali O. Effect of carbopol and polyvinylpyrrolidone on the mechanical, rheological and release properties of bioadhesive polyethylene glycol gels. AAPS Pharm Sci Tech. 2000;1(3):E24.
27. Washington N, Washington C, Wilson CG. Drug delivery to the oral cavity or mouth. In: Taylor and Francis Inc., editors. Physiological Pharmaceutics: Barriers to drug absorption. 2nd ed. New York; 2001. p. 38-58.
28. Vertzoni M, Dressman JB, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm. 2005;60(3):413-7.
29. Vidon N, Pfeiffer A, Godbillon J, Rongier M, Gauron S, Hirtz J, et al. Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac. Br J Clin Pharmacol. 1989;28(1):121-4.
30. Zhao L, Li Y, Fang L, Ren C, Xu Y, He Z. Effect of O-acylmenthol and salt formation on the skin permeation of diclofenac acid. Drug Dev Ind Pharm. 2009;35(7):814-26.
31. Adeyeeye CM, Li PK. Analytical profiles of drug substances. In: Florey K, editor. Diclofenac sodium. New Jersey: Academic Press Inc.; 1990. 19:123-44.
32. Tudja P, Khan MZ, Mestrović E, Horvat M, Golja P. Thermal behaviour of diclofenac sodium: decomposition and melting characteristics. Chem Pharm Bull (Tokyo). 2001;49(10):1245-50.
33. Fini A, Garuti M, Fazio G, Alvarez-Fuentes J, Holgado MA. Diclofenac salts. I. Fractal and thermal analysis of sodium and potassium diclofenac salts. J Pharm Sci. 2001;90(12):2049-57.
34. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603-16.
35. Nelson E. Comparative dissolution rates of weak acids and their sodium salts. J Pharm Sci. 1958;47(4):297-9.
36. Olson NZ, Sunshine A, Zighelboim I, DeCastro A. Onset and duration of analgesia of diclofenac potassium in the treatment of postepisiotomy pain. Am J Ther. 1997;4(7-8):239-46.
37. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release. 2005;108(2-3):375-85.
38. Wilson CG, Washington N, Greaves JL, Kamali F, Rees JA, Sempik AK, et al. Bimodal release of ibuprofen in a sustained-release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int J Pharm. 1989;50(2):155-61.
39. Center for Drug Evaluation and Research. CDER data standards manual C-DRG-00201 Version 008 [Internet]. Silver Spring (MD): US Food and Drug Administration; c1992-2006 [updated 2009 Apr 30; cited 2009 Nov 19]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ ucm071666.htm.
40. European Directorate for Quality of Medicines and Healthcare. Pharmeuropa. 1998;10(4):547.
41. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27(8):886-92.
42. Racz I. Drug formulation. Wiley J & Sons, editors. Budapest; 1990. p. 352-86.
43. Oberle RL, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokin Biopharm. 1987;15(5):529-44.